CRISPR-Associated Tn7 Transposase Systems for Precise Genome Editing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current genome editing technologies lack affordable, easy-to-set-up, scalable, and versatile methods for targeted genome engineering in eukaryotic cells, limiting their application in biotechnology and medicine.
Innovation Solution
The development of engineered compositions comprising CRISPR-associated Tn7 transposases, Type I-F Cas proteins, and guide molecules for precise targeting and editing of nucleic acids, enabling targeted insertion and perturbation of gene transcripts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional genome editing technologies (designer zinc fingers, TALEs, homing meganucleases) are used, then targeted genome perturbations can be achieved, but the methods are expensive, complex to set up, and difficult to scale
Solution Approach 1:
The patent uses CRISPR-Cas systems as a simpler copy or alternative to complex zinc finger and TALE proteins. Instead of designing entirely new complex proteins for each target, the system uses a guide RNA that can be easily synthesized to match any target sequence, copying the targeting function through a simpler molecular mechanism
Solution Approach 2:
The CRISPR-Cas system provides universal targeting capability through the guide RNA, which can be programmed to recognize any DNA sequence. The same Cas protein machinery can target multiple different genomic locations by simply changing the guide RNA sequence, making the system multi-functional and highly adaptable
2Manufacturing precision
If traditional genome editing technologies are used, then targeted genome perturbations can be achieved, but the methods are not scalable and difficult to target multiple positions simultaneously
Solution Approach 1:
The system segments the targeting function into two independent components: the Cas protein machinery and the guide RNA. This allows multiple guide RNAs to be used simultaneously with a single Cas protein, enabling parallel editing at multiple genomic positions and significantly increasing productivity
Solution Approach 2:
The system is highly dynamic and adaptable - guide RNAs can be quickly redesigned and synthesized to target new sequences without changing the Cas protein itself. This dynamic reprogramming capability allows rapid scaling from single-target to multi-target experiments
3Ease of manufacture
If affordable and easy-to-set-up methods are prioritized, then accessibility improves, but precision and reliability of genome editing may be compromised
Solution Approach 1:
The patent replaces complex protein-protein interactions (zinc fingers, TALEs) with RNA-DNA hybridization (CRISPR guide RNA). This substitution uses a more reliable and better-understood molecular recognition mechanism (base pairing) that is easier to design and more predictable in its binding behavior
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for efficient and precise editing of eukaryotic genomes, facilitating advanced biotechnological and medical applications by enabling selective mutations and gene corrections.
Implementation Method 1
a guide molecule capable of complexing with the one or more Type I-F Cas proteins and directing binding of the guide-Cas protein complex to a target polynucleotide
Implementation Method 2
one or more CRISPR-associated Tn7 transposases or functional fragments thereof
Data Source
AI summary
Systems and methods for targeted gene modification, targeted insertion, perturbation of gene transcripts, and nucleic acid editing. The novel nucleic acid targeting systems can comprise components of one or more transposases, one or more components of a CRISPR-Cas system, and a transposable element.